1. Scrip
  2. >>Business
  3. >>Manufacturing

China API Juggernaut Rolls On But Can India Recoup?

 
• By Anju Ghangurde

Report: India’s huge dependence on Chinese active pharmaceutical ingredients (APIs), including in high disease burden areas, poses heightened risks to its health security and requires “urgent interventions.”

Pills
INDIA'S HIGH DEPENDENCE ON CHINA FOR APIs IS A CAUSE FOR WORRY

India could be staring at a national health crisis in the backdrop of its continuing massive reliance on Chinese active pharmaceutical ingredients (APIs), including those used in drugs for high-burden diseases such as diabetes and cardiovascular ailments, according to a report by the professional services firm KPMG and the Confederation of Indian Industry (CII).

India accounts for 20% of the global disease burden and in addition to communicable diseases such as malaria and tuberculosis, the growing numbers for non-communicable diseases (NCDs) pose additional health...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.